Correction to: Bridging the Gap Between RCTs and RWE Through Endpoint Selection
Ther Innov Regul Sci
.
2021 Jan;55(1):97.
doi: 10.1007/s43441-020-00225-0.
Authors
Robert J LoCasale
1
,
Chris L Pashos
2
,
Ben Gutierrez
3
,
Nancy A Dreyer
4
,
Toby Collins
5
,
Alan Calleja
5
,
Michael J Seewald
6
,
Jonathan M Plumb
7
,
Johan Liwing
8
,
Maurille Feudjo Tepie
9
,
Sajan Khosla
10
Affiliations
1
Real World Evidence, Sanofi, Bridgewater, NJ, USA.
2
AbbVie, Chicago, IL, USA.
3
GSK, Philadelphia, PA, USA.
4
IQVIA, Real-World Solutions, Cambridge, MA, USA.
5
IQVIA, Real-World Solutions, London, UK.
6
Novartis Pharma AG/Pharma Medical Affairs, Basel, Switzerland.
7
Ferring Pharmaceuticals SA, St Prex, Switzerland.
8
CellProtect Nordic Pharmaceuticals, Stockholm, Sweden.
9
Center for Observational Research, Amgen, Cambridge, UK.
10
Real-World Evidence, Oncology R&D, AstraZeneca, Cambridge, UK. sajan.khosla@astrazeneca.com.
PMID:
33128171
PMCID:
PMC7852907
DOI:
10.1007/s43441-020-00225-0
No abstract available
Publication types
Published Erratum